TR201907702T4 - Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri. - Google Patents
Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri. Download PDFInfo
- Publication number
- TR201907702T4 TR201907702T4 TR2019/07702T TR201907702T TR201907702T4 TR 201907702 T4 TR201907702 T4 TR 201907702T4 TR 2019/07702 T TR2019/07702 T TR 2019/07702T TR 201907702 T TR201907702 T TR 201907702T TR 201907702 T4 TR201907702 T4 TR 201907702T4
- Authority
- TR
- Turkey
- Prior art keywords
- disorders
- modulators
- tnf activity
- derivatives
- relates
- Prior art date
Links
- 150000008523 triazolopyridines Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- AYSYSOQSKKDJJY-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]pyridine Chemical class C1=CC=CN2C=NN=C21 AYSYSOQSKKDJJY-UHFFFAOYSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000003040 nociceptive effect Effects 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Mevcut buluş, kaynaştırılmış bir triazol türev sınıfı ve bunların terapide kullanımı ile ilgilidir. Daha belirli bir biçimde, bu buluş farmakolojik olarak aktif sübstitüe edilmiş [1,2,4]triazolo[4,3-a]piridin türevleri ile ilgilidir. Bu bileşikler, TNFα#&'nın sinyalleşme modülatörleridir ve buna göre, özellikle advers inflamatuar ve otoimmün bozuklukların, nörolojik ve nörodejeneratif bozuklukların, ağrı ve nosiseptif bozuklukların, metabolik bozuklukların, oküler bozuklukların ve onkolojik bozuklukların tedavisinde farmasötik ajanlar olarak faydalıdır.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1321742.7A GB201321742D0 (en) | 2013-12-09 | 2013-12-09 | Therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201907702T4 true TR201907702T4 (tr) | 2019-06-21 |
Family
ID=50000425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/07702T TR201907702T4 (tr) | 2013-12-09 | 2014-12-08 | Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri. |
Country Status (11)
Country | Link |
---|---|
US (1) | US9850240B2 (tr) |
EP (1) | EP3080109B1 (tr) |
JP (1) | JP6426185B2 (tr) |
CN (1) | CN105814043B (tr) |
BR (1) | BR112016011844B1 (tr) |
CA (1) | CA2931578C (tr) |
ES (1) | ES2730942T3 (tr) |
GB (1) | GB201321742D0 (tr) |
RU (1) | RU2677697C1 (tr) |
TR (1) | TR201907702T4 (tr) |
WO (1) | WO2015086496A1 (tr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201321735D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
WO2016149436A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
WO2016149437A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
ES2803650T3 (es) | 2015-03-18 | 2021-01-28 | Bristol Myers Squibb Co | Compuestos heterocíclicos útiles como inhibidores de TNF |
WO2016168633A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
TW201702247A (zh) | 2015-04-17 | 2017-01-16 | 艾伯維有限公司 | 作為tnf信號傳遞調節劑之吲唑酮 |
TW201710257A (zh) | 2015-04-17 | 2017-03-16 | 艾伯維有限公司 | Tnf信號傳遞之三環調節劑 |
GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
CA2994703A1 (en) | 2015-08-03 | 2017-02-09 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of tnf alpha |
GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
WO2019192533A1 (zh) * | 2018-04-04 | 2019-10-10 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601952B1 (fr) * | 1986-07-23 | 1988-11-25 | Carpibem | Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques |
DE10038019A1 (de) * | 2000-08-04 | 2002-02-14 | Bayer Ag | Substituierte Triazolopyrid(az)ine |
MXPA03008144A (es) * | 2001-03-09 | 2003-12-12 | Pfizer Prod Inc | Nuevos compuestos antiinflamatorios de triazolopiridinas. |
CN2783538Y (zh) | 2004-08-04 | 2006-05-24 | 蒋沛康 | 无电线电池按扣 |
CA2577478A1 (en) * | 2004-08-18 | 2006-02-23 | Pharmacia & Upjohn Company Llc | Triazolopyridine compounds |
US7579360B2 (en) * | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US7572807B2 (en) * | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
ATE542818T1 (de) * | 2006-10-11 | 2012-02-15 | Amgen Inc | Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung |
US8119658B2 (en) * | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8324241B2 (en) * | 2008-04-11 | 2012-12-04 | Bristol-Myers Squibb Company | Triazolo compounds useful as DGAT1 inhibitors |
FR2933980B1 (fr) * | 2008-07-18 | 2011-07-29 | Sanofi Aventis | Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
CA2730959A1 (fr) * | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | Nouveaux derives triazolo[4,3-a]pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為pim激酶抑制劑之三唑吡啶化合物 |
WO2010022081A1 (en) * | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
DE102008063667A1 (de) * | 2008-12-18 | 2010-07-01 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate |
US8557797B2 (en) * | 2009-02-17 | 2013-10-15 | Chiesi Farmaceutici S.P.A. | Triazolopyridine derivatives and their therapeutic use |
PL2464645T3 (pl) * | 2009-07-27 | 2017-12-29 | Gilead Sciences, Inc. | Skondensowane heterocykliczne związki jako modulatory kanałów jonowych |
FR2966471A1 (fr) * | 2010-09-20 | 2012-04-27 | Valeo Vision | Piece de vehicule automobile en materiau a base de polymere (s) traite en surface |
WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
BR112014006223A8 (pt) * | 2011-09-15 | 2018-01-09 | Novartis Ag | 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação |
CN103130792B (zh) * | 2011-11-30 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种2-氨基噻唑类化合物 |
US9458154B2 (en) | 2011-12-09 | 2016-10-04 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
WO2013134079A1 (en) * | 2012-03-05 | 2013-09-12 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
US8765767B2 (en) | 2012-03-16 | 2014-07-01 | Bristol-Myers Squibb Company | Positive allosteric modulators of mGluR2 |
EP2858983B1 (en) | 2012-06-11 | 2018-04-18 | UCB Biopharma SPRL | Tnf-alpha modulating benzimidazoles |
US9309243B2 (en) | 2012-07-13 | 2016-04-12 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of TNF activity |
GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
-
2013
- 2013-12-09 GB GBGB1321742.7A patent/GB201321742D0/en not_active Ceased
-
2014
- 2014-12-08 RU RU2016127228A patent/RU2677697C1/ru active
- 2014-12-08 CN CN201480067043.XA patent/CN105814043B/zh not_active Expired - Fee Related
- 2014-12-08 JP JP2016537531A patent/JP6426185B2/ja not_active Expired - Fee Related
- 2014-12-08 WO PCT/EP2014/076832 patent/WO2015086496A1/en active Application Filing
- 2014-12-08 EP EP14808638.2A patent/EP3080109B1/en active Active
- 2014-12-08 BR BR112016011844-8A patent/BR112016011844B1/pt not_active IP Right Cessation
- 2014-12-08 CA CA2931578A patent/CA2931578C/en active Active
- 2014-12-08 US US15/101,044 patent/US9850240B2/en active Active
- 2014-12-08 TR TR2019/07702T patent/TR201907702T4/tr unknown
- 2014-12-08 ES ES14808638T patent/ES2730942T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
EP3080109B1 (en) | 2019-05-15 |
CN105814043A (zh) | 2016-07-27 |
JP2016539971A (ja) | 2016-12-22 |
EP3080109A1 (en) | 2016-10-19 |
ES2730942T3 (es) | 2019-11-13 |
CA2931578A1 (en) | 2015-06-18 |
CN105814043B (zh) | 2019-05-17 |
GB201321742D0 (en) | 2014-01-22 |
CA2931578C (en) | 2021-10-26 |
US20160304512A1 (en) | 2016-10-20 |
WO2015086496A1 (en) | 2015-06-18 |
US9850240B2 (en) | 2017-12-26 |
JP6426185B2 (ja) | 2018-11-21 |
RU2677697C1 (ru) | 2019-01-21 |
BR112016011844A2 (tr) | 2017-08-08 |
BR112016011844B1 (pt) | 2022-08-16 |
RU2016127228A (ru) | 2018-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201907702T4 (tr) | Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri. | |
TR201909614T4 (tr) | Tnf aktivitesinin modülatörleri olarak kaynaşık imidazol ve pirazol türevleri. | |
TR201908447T4 (tr) | Tnf aktivitesinin modülatörleri olarak kaynaşık imidazol ve pirazol türevleri. | |
BR112016012990A2 (pt) | Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf | |
EA201500133A1 (ru) | Производные имидазопиразина в качестве модуляторов активности tnf | |
EA201500130A1 (ru) | Производные имидазопиридина в качестве модуляторов активности tnf | |
BR112016011484A2 (pt) | Derivados de imidazopirimidina como moduladores de atividade de tnf | |
BR112016012997A2 (pt) | Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf | |
CA2931589C (en) | Fused bicyclic heteroaromatic derivatives as modulators of tnf activity | |
EA201790734A1 (ru) | Конденсированные пентациклические производные имидазола | |
BR112016011483A2 (pt) | Derivados de imidazotriazina como moduladores de atividade de tnf | |
BR112016013012A2 (pt) | Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf | |
EA201401350A1 (ru) | Бензимидазолы, модулирующие tnf-альфа | |
BR112016011485A2 (pt) | Derivados de imidazopiridazina como moduladores de atividade de tnf | |
TR201910983T4 (tr) | Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri. | |
BR112016011794A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
BR112016011792A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
BR112016012242A2 (pt) | Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf | |
TR201908163T4 (tr) | Tnf aktivitesinin modülatörleri olarak pirazolopiridin türevleri. | |
BR112016011789A2 (pt) | Derivados de purina, composição farmacêutica compreendendo os mesmos e uso dos mesmos | |
BR112016012258A2 (pt) | Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf | |
BR112016012254A2 (pt) | Derivados de triazolpiridazina como moduladores de atividade de tnf | |
BR112016012261A2 (pt) | Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf | |
BR112016011527A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
BR112018069936A2 (pt) | derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf |